The amphetamine-like reinforcing effect and mechanism of L-deprenyl on conditioned place preference in mice

European Journal of Pharmacology

Volumn 364, Issue 1, 1999, Pages 1-6

  Wu, Wei Ran ^a   Zhu, Xing Zu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Dopamine; Haloperidol; L Amphetamine; L Deprenyl; MPTP (1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine); Reinforcement

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONDITIONING; DOPAMINERGIC SYSTEM; DOSE RESPONSE; ELECTROCHEMICAL DETECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMPHETAMINE; ANIMALS; CONDITIONING, OPERANT; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE INHIBITORS; REINFORCEMENT (PSYCHOLOGY); SELEGILINE;

EID: 0032928243     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00831-0     Document Type: Article

References (48)

1. +) analogs: in vivo neurotoxicity and inhibition of striatal synaptosomal dopamine uptake. Eur. J. Pharmacol. 166:1989;65-74.
2. 2+ channel blockade prevents lysergic acid diethylamide-induced changes in dopamine and serotonin metabolism. Eur. J. Pharmacol. 332:1997;9-14.
3. Bals-Kubik R., Albertiner A., Herz A., Shippenberg T.S. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J. Pharmacol. Exp. Ther. 264:1993;489-495.
4. Bardo M.T. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit. Rev. Neurobiol. 12:1998;37-67.
5. Birkmayer W., Riederer P., Youdim M.B.H., Linauer W. The potential of the anti-akinetic effect of L-DOPA treatment by an inhibitor of MAO-B, (-)deprenyl. J. Neural Transm. 36:1975;303-326.
6. Carr G.D., White N.M. Anatomical disassociation of amphetamine's rewarding and aversive effects: an intracranial microinjection study. Psychopharmacology. 89:1986;340-346.
7. 3H ]mazindol Neuroscience. 49:1992;317-327.
8. File S.E. Aversive and appetitive properties of anxigenic and anxioltic agents. Behav. Brain Res. 21:1986;189-194.
9. Gerlach M., Youdim M.B.H., Riederer P. Pharmacology of selegiline. Neurology. 47:1996;S137-S145. Suppl. 3.
10. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 311:1984;467-469.
11. Heinonen E.H., Anttila M.I., Lammintausta A.S. Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther. 56:1994;742-749.
12. + toxicity: role of BDNF gene expression. Brain Res. Mol. Brain. Res. 41:1996;14-26.
13. Hung H.C., Lee E.H. MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. Free Radic. Biol. Med. 24:1998;76-84.
14. + in the nigrostriatal and mesolimbic dopaminergic pathways. Neurosci. Lett. 196:1995;93-96.
15. Johanson C.E., Barrett J.E. The discriminative stimulus effects of cocaine in pigeons. J. Pharmacol. Exp. Ther. 267:1993;1-8.
16. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev. 18:1993;75-82.
17. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol. Scand. 95(Suppl.):1983;57-80.
18. Knoll J. Striatal dopamine dependency of life span in male rats: longevity study with L-deprenyl. Mech. Ageing Dev. 46:1988;237-262.
19. Liu Z.H., Zhang K.G. Conditioned place preference and its neurochemical mechanisms. Chin. Bull. Drug Depend. 5:1996;193-196.
20. Mann J.J., Aarons S.F., Wilner P.J. A controlled study of the antidepressant efficacy and side-effects of L-deprenyl. Arch. Gen. Psychiatry. 46:1989;45-50.
21. McGregor A., Baker G., Roberts D.C.S. Effects of 6-hydroxydopamine lesions of the medial prefrontal cortex on intravenous self-administration under a progressive ratio schedule of reinforcement. Pharmacol. Biochem. Behav. 53:1996;5-9.
22. Mendlenicz J., Youdim M.B.H. L-Deprenyl, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double-blind evaluation. Br. J. Psychiatry. 142:1983;508-511.
23. Menza M.A., Golbe L.I., Cody R.A., Forman N.E. Dopamine-related personality traits in Parkinson's disease. Neurology. 43:1993;505-508.
24. Monteverde A., Gnemmi P., Rossi F. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin. Ther. 12:1990;315-332.
25. Morgenthaler J. Smart drug update. Mondo 2000. 5:1992;36-37.
26. Myllyla V.V., Sotaniemi K.A., Tuominen J., Heinonen E.H. Selegiline as primary treatment in early phase of Parkinson's disease - an interim report. Acta Neurol. Scand. 126:1989;177-182.
27. Nickel B., Szelenyi I., Schulze G. Evaluation of physical dependence liability of L-deprenyl (selegiline) in animals. Clin. Pharmacol. Ther. 56:1994;757-767.
28. Ortmann R., Schaub M., Felner A., Lauber J., Christen P., Waldmeier P.C. Phenylethylamine-induced stereotype in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology. 84:1984;22-27.
29. Porsolt R.D., Pawelec C., Jalfre M. Discrimination of amphetamine cue: effects of A, B and mixed type inhibitors of monoamine oxidase. Neuropharmacology. 23:1984;569-573.
30. Risner M.E., Jones B.E. Characteristics of β-phenylethylamine self-administration by dog. Pharmacol. Biochem. Behav. 36:1977;1731-1735.
31. Salonen J.S. Determination of amine metabolites of selegiline in biological fluids by capillary gas chromatography. J. Chromatogr. 527:1990;163-168.
32. Schneider L.S., Tariot P.N., Goldstein B. Therapy with L-deprenyl (selegiline) and relation to abuse liability. Clin. Pharmacol. Ther. 56:1994;750-756.
33. Shannon H.E., De Georgio C.M. Self-administration of the endogenous trace amines β-phenylethylamine, N-methylphenylethylamine and phenylethanolamine in dogs. J. Pharmacol. Exp. Ther. 222:1982;52-60.
34. 2 dopamine receptors. J. Pharmacol. Exp. Ther. 265:1993;53-59.
35. Tao Q., Zheng J.W. Conditioned place preference paradigm. Chin. Bull. Drug Depend. 5:1996;68-73.
36. Tariot, P.N., Schneider, L.S., Patel, S.V., Goldstein, B., 1993. Alzheimer's disease and L-deprenyl: rationale and findings. In: Szelenyi, I. (Ed.), Inhibitors of Monoamine Oxidase B. Birkhauser, Basal, pp. 301-317.
37. The Parkins Study Group Effect of deprenyl on the progression of disability in early Parkinson's disease. New Engl. J. Med. 321:1989;1363-1371.
38. The Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl. J. Med. 328:1993;176-183.
39. Timar J., Knoll B. The effect of repeated administration of L-deprenyl on the phenylethylamine-induced stereotypy in rats. Arch. Int. Pharmacodyn. 279:1986;50-60.
40. 2 agonists injected peripherally or into nucleus accumbens. Psychopharmacology. 103:1991;271-276.
41. Winger G.D., Yasar S., Negus S.S., Goldberg S.R. Intravenous self-administration studies with L-deprenyl (selegiline) in monkeys. Clin. Pharmacol. Ther. 56:1994;774-780.
42. Wu W.-R., Zhu X.-Z., Guan H.-J., Wang R.-G., Ji X.-Q. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity. Acta Pharmacol. Sin. 20:1999;138-142.
43. Yasar S., Bergman J. Amphetamine-like effects of L-deprenyl in drug discrimination studies. Clin. Pharmacol. Ther. 56:1994;768-773.
44. Yasar S., Schindler C.W., Thorndike E.B., Szelenyi I., Goldberg S.R. Evaluation of stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats. J. Pharmacol. Exp. Ther. 265:1993;1-6.
45. Yasar, S., Winger, G., Nickel, B., Schulze, G., Goldberg, S.R., 1993b. Preclinical evaluation of L-deprenyl: lack of amphetamine like abuse potential. In: Szelenyi, I. (Ed.), Inhibitors of Monoamine Oxidase B. Birkhauser, Basal, pp. 215-233.
46. Yasar S., Schindler C.W., Thorndike E.B., Goldberg S.R. Evaluation of deprenyl for cocaine-like discriminative stimulus effects in rats. Eur. J. Pharmacol. 259:1994;243-256.
47. Yokel, R.A., 1987. Intravenous self-administration: response rates, the effects of pharmacological challenges, and drug preference. In: Bozarth, M.A. (Ed.), Methods of Assessing the Reinforcing Properties of Abused Drugs. Springer-Verlag, New York, NY, pp. 1-22.
48. Zheng J.W., Lu S.N., Groldberg S.R. Abuse liability of L-deprenyl. Clin. Bull. Drug Depend. 4:1995;254-256.